Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms)

Sep 7, 2016
533 Pages - Pub ID: KLI15104387
Share this report
 
Online Download $4,500
Departmental Site License (one location, up to 10 users) $6,750
Global Site License $9,000
Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms)

The sequencing market is already a large market with an estimated $3.8 billion inproduct revenues in 2015. This includes capillary electrophoresis sequencing systems(based on the early Sanger sequencing method) and also the rapidly growing nextgeneration sequencing market. This estimate of $3.8 million includes both sequencinginstruments plus consumables, and also service revenue such as from extendedinstrument service contracts.  It is a large and rapidly growing market.  

Clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events. Next Generation Sequencing Markets examines the segments of the sequencing market, including sequencing instruments plus consumables and also service revenue such as from extended instrument service contracts, with analysis of the full sequencing market including:
  • Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2015 and 2020
  • Sequencing Market, Worldwide, 2015 and 2020 (Instrument Revenue, Consumables Revenue, Services Revenue, Total Market)
  • Market Share of Sequencing Market, By Company (Instruments, Consumables, Services Relating to Supporting Products)
  • Sequencing Market by Geographical Region, Worldwide, 2015 and 2020 (North America, Europe, Asia, Rest of World, Total Market)
  • Next Generation Sequencing System Ownership by Country, Percentage (United States, China, Germany, UK, South Korea, Spain, Canada, France, Australia, Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, Others)
  • Next Generation Sequencing System Ownership by Brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq)
  • Percent of End Users (Academic & Government versus Commercial, Non-Profit & Hospital), 2014, 2015, and 2018 (projected)
  • Research Sequencing Market – Types of Sequencing: Targeted or Whole Exome Sequencing versus de novo or Whole Genome Sequencing (2015)
  • Clinical Sequencing Market by Disease Category, 2015, Percentage (Genetic Testing/Inherited Disorders, Other Disorders)
  • Clinical Sequencing Market by Disease Category, 2020, Percentage (Oncology, Genetic Testing/Inherited Disorders, Infectious Disease, Other Disorders)
  • Investments in Next Generation Sequencing Companies, 2015 and First Half of 2016
Growth in the research market and also in clinical applications of next generation sequencing – as demonstrated by the rapid growth of the market leader and the market as a whole – is being driven by several factors. As discussed in the report, these include the following market drivers:
  • Advances in Technology
  • Increasing Number of Clinical Applications for Next Generation Sequencing
  • Cancer Diagnostic Market Drivers
  • Genetic Analysis [Inherited Disorders, Prenatal and Postnatal Diagnostics] Market Drivers
  • Infectious Disease Diagnostic Market Drivers
DNA sequencing has successfully penetrated the research market. This market is expected to continue to grow, despite funding issues and other challenges. DNA sequencing is also penetrating the clinical diagnostic market. The sequencing field has entered an exciting time where it is now becoming possible to realize some of the potential benefits long dreamed about by researchers and companies in this field, though improvements in sequencing technology are still needed in order to make sequencing based diagnostic tests widely available and used by all physicians.

DNA sequencing has become a competitive field with companies developing or offering newer, proprietary nucleic acid sequencing technologies. The report discusses new technologies, among these Massively Parallel Signature Sequencing (MPSS), Pyrosequencing, 454 Technology, Sequencing by Synthesis (SBS), Supported Oligonucleotide Ligation and Detection (SOLiD), Ion Torrent Sequencing, Single Molecule Real Time (SMRT) Sequencing, DNA Nano Ball Sequencing, and Nanopore Sequencing. New technologies are summarized as well, including:
  • Current and Emerging Sequencing Technologies and Platforms
  • Selected Companies Developing/Marketing Products for NGS Sample or Library Preparation
  • Selected Companies Developing/Marketing NGS Information Technology Solutions
  • Selected Companies Developing NGS Sample-to-Answer (Sample-to-Insight) Platforms
  • Selected Companies Developing Rapid NGS Assays or Platforms
Most currently available clinical tests based on next generation sequencing are laboratory developed tests (LDTs). The first next generation sequencing system and in vitro diagnostic tests have been cleared by the FDA, and more will follow. The next generation sequencing clinical diagnostic market is poised for continued rapid growth over the next several years.

Next generation sequencing is increasingly being used in the field of personalized medicine and companion diagnostics. For example, in oncology, pharmaceutical companies are developing and commercializing a growing number of targeted therapies. This has generated a need for assays that detect the presence or absence of increasingly more genetic markers, all from a small sample of tissue. In other words, multiplexed assays and/or panels are needed. This, in turn, has led to increased interest in technologies such as next-generation sequencing, which can be used to interrogate a large number of genes in a single assay. The report covers NGS applications in cancer diagnostics, including NGS-based tests for oncology and liquid biopsies; genetic analysis – inherited disorders, prenatal and postnatal diagnostics; infectious disease diagnostics; human leukocyte antigen (HLA) testing; and other diagnostic applications of sequencing, including in the direct-to-consumer genetic testing industry. The report notes the following:
  • Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Oncology
  • Selected Companies Developing and/or Marketing Liquid Biopsy Assays
  • Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Genetic Analysis [Inherited Disorders, Prenatal and Postnatal Diagnostics]
  • Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Infectious Diseases
  • Selected Companies Offering Products/Services for Applications of DNA Sequencing in Human Leukocyte Antigen (HLA) Testing
  • Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Other Diagnostic Applications
Collaborations are an essential part of the growing sequencing market. The impact of deals in the sequencing marketplace is discussed in detail in this report:
  • Selected Investment and Financing Agreements in Next Generation Sequencing Companies [Includes IT Companies in NGS]
  • Selected Acquisitions of Next Generation Sequencing Companies [Includes IT Companies in NGS]
  • Selected Agreements between Next Generation Sequencing Companies and Diagnostic Companies or Clinical Laboratories [Includes IT Companies in NGS]
  • Examples of Diagnostic Companies and Clinical Laboratories That Have Made Agreements in Next Generation Sequencing
  • Selected Agreements between Next Generation Sequencing Companies and Pharmaceutical or Biopharmaceutical Companies [Includes Contract Research Organizations Providing Services to Pharma Companies]
  • Selected Pharmaceutical and Biopharmaceutical Companies Using or Active in Next Generation Sequencing
  • Selected Company Agreements between Two Next Generation Sequencing Companies [Includes IT Companies in NGS]
  • Selected Other Next-Generation Sequencing Company Agreements in Next Generation Sequencing [Includes IT Companies in NGS]
  • Selected Next Generation Sequencing Company Agreements with Academic or Other Non-Profit Organizations [Includes IT Companies in NGS]
Profiles of companies in Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms) reflect the wide range next generation sequencing products, including sample preparation, sequencing, and data analysis. Companies profiled include:
  • 10x Genomics, Inc.
  • 23andMe, Inc.
  • Abbott Laboratories
  • ACT Genomics Co., Ltd.
  • Adaptive Biotechnologies Corporation
  • Admera Health
  • Advanced Biological Laboratories (ABL), S.A.
  • Agilent Technologies Inc.
  • AltheaDx, Inc.
  • Ambry Genetics Corp.
  • Aperiomics, Inc.
  • Asuragen, Inc.
  • Athena Diagnostics, Inc. (A Quest Diagnostics Business)
  • Base4 Innovation Ltd
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
  • Becton, Dickinson and Company (BD)
  • BGI
  • Bina Technologies, Inc. (Part of Roche Sequencing)
  • BioDiscovery, Inc.
  • Biomatters Ltd.
  • bioMérieux S.A.
  • bioTheranostics, Inc.
  • Cancer Genetics, Inc.
  • CareDx, Inc.
  • Caris Life Sciences
  • CLC bio (A QIAGEN Company)
  • Color Genomics, Inc.
  • Complete Genomics (A BGI Company)
  • Courtagen Life Sciences, Inc.
  • Cynvenio Biosystems, Inc.
  • DNA Electronics Ltd.
  • Eurofins Genomics
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • GATC Biotech AG
  • GenapSys, Inc.
  • GenDx
  • GENEWIZ Inc.
  • Genia Technologies, Inc. (Part of Roche Sequencing)
  • Genomic Health, Inc.
  • Genoptix (A Novartis Company)
  • GnuBIO, Inc. (A Bio-Rad Company)
  • GRAIL
  • Guardant Health, Inc.
  • Helix
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • Illumina, Inc.
  • Inivata Ltd.
  • Invitae Corporation
  • Invivoscribe Technologies, Inc.
  • Laboratory Corporation of America (LabCorp)
  • Lasergen, Inc.
  • MolecularMD Corporation
  • Myriad Genetics, Inc.
  • NANTOMICS (Member of the NantWorks ecosystem of companies)
  • Natera, Inc.
  • NeoGenomics, Inc./NeoGenomics Laboratories
  • N-of-One, Inc.
  • OncoDNA S.A.
  • Oncospire Genomics
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • Pathway Genomics Corporation
  • Personal Genome Diagnostics, Inc.
  • Personalis, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics
  • RainDance Technologies, Inc.
  • Roche
  • Siemens Healthcare Diagnostics
  • Stratos Genomics Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Technology advances in knowledge of the genome, and in DNA sequencing technology/platforms, will continue to fuel the growth of diagnostic applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories, and also in IVD companies that sell kits to clinical labs.


What's Creating the Interest in Sequencing?

The promise of DNA sequencing has attracted many companies, researchers, investors, and others. The sequencing market is now large, and is growing rapidly. Kalorama Information estimates that this market is growing at a CAGR of double digits.   Clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events. In January 2015, Roche and Foundation Medicine announced an agreement that is worth up to $1.2 billion. Roche agreed to acquire a majority interest in Foundation Medicine for approximately $780 million.  Companies are raising money: Just since the beginning of 2015, companies discussed in this report have raised over $3 billion in investments.

Are Pharmaceutical Companies Involved in this Market?
Companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. Over twelve agreements with pharmaceutical companies since the beginning of 2016 are discussed in this report.   In March 2015, Illumina announced a collaboration with Merck Serono to develop a universal next-generation sequencing-based oncology

What Stage of Clinical Use of NGS Are We At?

It's happening and it's growing.   While next generation sequencing has been used for some clinical applications for a while, this is becoming more widespread and some next generation sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model. Illumina’s MiSeqDx was the first cleared in vitro diagnostic next generation sequencing system. MiSeqDx is also CE marked, and FDA-cleared tests are currently available on this platform. Illumina is
continuing to develop products for the IVD market. In August 2014, Illumina announced collaborative strategic partnerships with AstraZeneca, Janssen, and Sanofi to develop a next-generation sequencing based test for use during clinical trials, and eventually resulting in a multi-gene panel to be used to select therapies.   Both of these announcements included comments regarding regulatory approval as well as commercialization.

What's the Regulatory Status of NGS in Clinical Settings?

The path to development of FDA approved or cleared tests will become better understood when the FDA issues guidances regarding regulation of next generation sequencing based tests. An important step in this processes occurred

Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview
Future Prospects in the Sequencing Market
Chapter 2: Introduction
Overview – Next Generation Sequencing Market Is Rapidly Changing
History of DNA Sequencing
Point-of-View
Chapter 3: Sequencing Technology
Sanger Sequencing
Next-Generation Sequencing
Massively Parallel Signature Sequencing (MPSS)
Pyrosequencing
454 Technology
Sequencing by Synthesis (SBS)
Supported Oligonucleotide Ligation and Detection (SOLiD)
Ion Torrent Sequencing
Single Molecule Real Time (SMRT) Sequencing
DNA Nano Ball Sequencing
Nanopore Sequencing
Other Sequencing Technologies
Sequencing Applications/Types of Sequencing
Sample or Library Preparation
Information Technology
Sample-to-Answer (Sample-to-Insight) Workflows or Platforms
Rapid Next Generation Sequencing Testing
Chapter 4: Sequencing Applications
Research, Drug Discovery and Development
Clinical Diagnostic Applications of Sequencing
Cancer Diagnostics: NGS Based Tests for Oncology
Cancer Diagnostics: Liquid Biopsies
Genetic Analysis – Inherited Disorders, Prenatal and Postnatal Diagnostics
Infectious Disease Diagnostics
Human Leukocyte Antigen (HLA) Testing
Other Diagnostic Applications of Sequencing
Direct-to-Consumer Genetic Testing Industry
Chapter 5: Deals – Next Generation Sequencing Companies
Investments and Financing Agreements
Mergers and Acquisitions
Other Corporate Agreements and Collaborations
Collaborations/Agreements with Diagnostic Companies and/or Clinical Laboratories
Collaborations/Agreements with Pharmaceutical and Biopharmaceutical Companies
Collaborations/Agreements between Two Companies in Next Generation Sequencing
Other Company Collaborations/Agreements
Collaborations and Other Agreements with Universities, Non-Profit Research Institutes and Government
Chapter 6: Applying Sequencing to Diagnostics – Market Drivers and Challenges
Overcoming Technology Hurdles – Sample Preparation and Data Analysis
Advances in Next Generation Sequencing Platforms
Next Generation Sequencing Market Drivers
Advances in Technology
Research Market Drivers
Increasing Number of Clinical Applications for Next Generation Sequencing
Cancer Diagnostic Market Drivers
Genetic Analysis [Inherited Disorders, Prenatal and Postnatal Diagnostics] Market Drivers
Infectious Disease Diagnostic Market Drivers
Market Drivers for Other Segments of the Diagnostic Market
Issues and Hurdles Faced by NGS Companies Selling to the Research Market
Issues and Hurdles Faced by Clinical Laboratories Doing NGS
Regulation of Next Generation Sequencing-Based In Vitro Diagnostic (IVD) Tests
Regulation of Companion Diagnostics
Complexities of Companion Diagnostic Tests and Corresponding Therapeutic Products; Harmonization of Companion Diagnostic Tests Across a Class of Targeted Therapies
Cost and Reimbursement Issues
Competition
Future Prospects
Chapter 7: Sequencing Market Analysis
Sequencing Market Overview
Sequencing Market – Geographical Distribution
Brand Ownership
Sequencing Market – Research versus Clinical Use
Sequencing Methods/Applications
Clinical Sequencing Market – Disease Indications
Analysis of Deals Activity in Next Generation Sequencing
Chapter 8: Company Profiles - Next Generation Sequencing Companies
10x Genomics, Inc.
23andMe, Inc.
Abbott Laboratories
Recent Revenue History
Company Overview – With a Focus on Sequencing
ACT Genomics Co., Ltd.
Adaptive Biotechnologies Corporation
Admera Health
Advanced Biological Laboratories (ABL), S.A
Agilent Technologies Inc.
Recent Revenue History
Company Overview
AltheaDx, Inc.
Ambry Genetics Corp.
Aperiomics, Inc.
Asuragen, Inc.
Athena Diagnostics, Inc. (A Quest Diagnostics Business)
Base4 Innovation Ltd
Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
Revenue History
Company Overview
Becton, Dickinson and Company (BD)
Recent Revenue History
Company Overview
BGI
Bina Technologies, Inc. (Part of Roche Sequencing)
BioDiscovery, Inc.
Biomatters Ltd.
bioMérieux SA
Recent Revenue History
Company Overview
bioTheranostics, Inc.
Cancer Genetics, Inc.
Recent Revenue History
Company Overview
CareDx, Inc.
Recent Revenue History
Company Overview
Caris Life Sciences
CLC bio (A QIAGEN Company)
Color Genomics, Inc.
Complete Genomics (A BGI Company)
Courtagen Life Sciences, Inc.
Cynvenio Biosystems, Inc.
DNA Electronics Ltd.
Eurofins Genomics
Exosome Diagnostics, Inc.
Foundation Medicine, Inc.
Recent Revenue History
Company Overview
GATC Biotech AG
GenapSys, Inc.
GenDx
GENEWIZ Inc.
Genia Technologies, Inc. (Part of Roche Sequencing)
Genomic Health, Inc.
Recent Revenue History
Company Overview
Genoptix (A Novartis Company)
GnuBIO, Inc. (A Bio-Rad Company)
GRAIL
Guardant Health, Inc.
Helix
HTG Molecular Diagnostics
Recent Revenue History
Company Overview
Human Longevity, Inc.
Illumina, Inc.
Recent Revenue History
Company Overview
Inivata Ltd.
Invitae Corporation
Recent Revenue History
Company Overview
Invivoscribe Technologies, Inc.
Laboratory Corporation of America (LabCorp)
Recent Revenue History
Company Overview
Lasergen, Inc.
MolecularMD Corporation
Myriad Genetics, Inc.
Recent Revenue History
Company Overview
NANTOMICS (Member of the NantWorks ecosystem of companies)
Natera, Inc.
NeoGenomics, Inc./NeoGenomics Laboratories
Recent Revenue History
Company Overview
N-of-One, Inc.
OncoDNA SA
Oncospire Genomics
Oxford Nanopore Technologies Ltd.
Pacific Biosciences of California, Inc.
Recent Revenue History
Company Overview
Pathway Genomics Corporation
Personal Genome Diagnostics, Inc.
Personalis, Inc.
QIAGEN N.V.
Recent Revenue History
Company Overview
Quest Diagnostics
Recent Revenue History
Company Overview
RainDance Technologies, Inc.
Roche
Recent Revenue History
Company Overview
Siemens Healthcare Diagnostics
Recent Revenue History
Company Overview
Stratos Genomics Inc.
Sysmex Corporation
Recent Revenue History
Company Overview
Thermo Fisher Scientific, Inc.
Recent Revenue History
Company Overview
List of Exhibits
1: Executive Summary
Table 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2015 and 2020
3: Sequencing Technology
Table 3-1: Current and Emerging Sequencing Technologies and Platforms
Table 3-2: Selected Companies Developing/Marketing Products for NGS Sample or Library Preparation
Table 3-3: Selected Companies Developing/Marketing NGS Information Technology Solutions
Table 3-4: Selected Companies Developing NGS Sample-to-Answer(Sample-to-Insight) Platforms
Table 3-5: Selected Companies Developing Rapid NGS Assays or Platforms
4: Sequencing Applications
Table 4-1: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Oncology
Table 4-2: Selected Companies Developing and/or Marketing Liquid Biopsy Assays
Table 4-3: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Genetic Analysis [Inherited Disorders,Prenatal and Postnatal Diagnostics]
Table 4-4: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Infectious Diseases
Table 4-5: Selected Companies Offering Products/Services for Applications of DNA Sequencing in Human Leukocyte Antigen (HLA) Testing
Table 4-6: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Other Diagnostic Applications
5: Deals – Next Generation Sequencing Companies
Table 5-1: Selected Investment and Financing Agreements in Next Generation Sequencing Companies [Includes IT Companies in NGS]
Table 5-2: Selected Acquisitions of Next Generation Sequencing Companies[Includes IT Companies in NGS]
Table 5-3: Selected Agreements between Next Generation Sequencing Companies and Diagnostic Companies or Clinical Laboratories [Includes IT Companies in NGS]
Table 5-4: Examples of Diagnostic Companies and Clinical Laboratories That Have Made Agreements in Next Generation Sequencing
Table 5-5: Selected Agreements between Next Generation Sequencing Companies and Pharmaceutical or Biopharmaceutical Companies [Includes Contract Research Organizations Providing Services to Pharma Companies]
Table 5-6: Selected Pharmaceutical and Biopharmaceutical Companies Using or Active in Next Generation Sequencing
Table 5-7: Selected Company Agreements between Two Next Generation Sequencing Companies [Includes IT Companies in NGS]
Table 5-8: Selected Other Next-Generation Sequencing Company Agreements in Next Generation Sequencing [Includes IT Companies in NGS]
Table 5-9: Selected Next Generation Sequencing Company Agreements with Academic or Other Non-Profit Organizations [Includes IT Companies in NGS]
7: Sequencing Market Analysis
Table 7-1: Sequencing Market, Worldwide, 2015 and 2020 (Instrument Revenue, Consumables Revenue, Services Revenue, Total Market)
Table 7-2: Sequencing Market by Geographical Region, Worldwide, 2015 and 2020 (North America, Europe, Asia, Rest of World, Total Market)
Figure 7-2: Next Generation Sequencing System Ownership by Country, Percentage (United States, China, Germany, UK, South Korea, Spain, Canada, France, Australia, Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, Others)
Figure 7-3: Next Generation Sequencing System Ownership by Brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq)
Figure 7-5: Research Sequencing Market – Types of Sequencing: Targeted or Whole Exome Sequencing versus de novo or Whole Genome Sequencing (2015)
Figure 7-6: Clinical Sequencing Market by Disease Category, 2015, Percentage (Genetic Testing/Inherited Disorders, Other Disorders)
Figure 7-7: Clinical Sequencing Market by Disease Category, 2020, Percentage(Oncology, Genetic Testing/Inherited Disorders, Infectious Disease, Other Disorders)
Table 7-3: Investments in Next Generation Sequencing Companies, 2015 and First Half of 2016
8: Company Profiles - Next Generation Sequencing Companies
Table 8-1: Abbott Revenues (2013, 2014, 2015)
Table 8-2: Agilent Technologies Revenues (2013, 2014, 2015)
Table 8-3: Becton, Dickinson and Company (BD) Revenues (2013, 2014, 2015)
Table 8-4: bioMérieux Revenues (2013, 2014, 2015)
Table 8-5: bioMérieux Revenues (2014 and 2015) - By Region, and by Technology and Application
Table 8-6: Cancer Genetics Revenues (2013, 2014, 2015)
Table 8-7: CareDx Revenues (2013, 2014, 2015)
Table 8-8: Foundation Medicine Revenues (2013, 2014, 2015)
Table 8-9: Genomic Health Revenues (2013, 2014, 2015)
Table 8-10: HTG Molecular Diagnostics (2014 and 2015)
Table 8-11: Illumina (2013, 2014, 2015)
Table 8-12: Invitae Corporation Revenues (2013, 2014, 2015)
Table 8-13: Laboratory Corporation of America (LabCorp) Revenues (2013,2014, 2015)
Table 8-14: Myriad Genetics Revenues (2013, 2014, 2015)
Table 8-15: NeoGenomics Revenues (2013, 2014, 2015)
Table 8-16: Pacific Biosciences Revenues (2013, 2014, 2015)
Table 8-17: QIAGEN Revenues (2013, 2014, 2015)
Table 8-18: QIAGEN – Distribution of Sales in 2015
Table 8-19: Quest Diagnostics Revenues (2013, 2014, 2015)
Table 8-20: Roche Revenues (2014 and 2015)
Table 8-21: Siemens Revenues (2014 and 2015)
Table 8-22: Sysmex Revenues (2013, 2014, 2015)
Table 8-23: Thermo Fisher Scientific Revenues (2013, 2014, 2015)

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.